logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Maximilian J. Hochmair

karl landsteiner institute of lung research and pulmonary oncology
H指数:47
被引数:2.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Second-line therapy in extensive-stage small cell lung cancer: an unmet need highlighted by real-world evidence from the LALUCA registry

广泛期小细胞肺癌的二线治疗：LALUCA登记研究中的真实世界证据凸显了这一未满足的需求

Lung Cancer
IF4.4
2026-09-300
OA
Daniel Moser; Anna Lang-Stöberl; Hannah Fabikan; Julie Krainer-Jacobs; Oliver Illini; Leyla Ay; Nino Müser; Christoph Weinlinger; Vania Mikaela Rodriguez; Georg-Christian Funk; Marie-Kathrin Breyer; Robab Breyer-Kohansal; Arschang Valipour; Maximilian J. Hochmair
How safe and effective is radiosurgical treatment for patients with 10 or more BM?

对于有10个或更多脑转移瘤的患者，放射外科治疗的安全性和有效性如何？

Neuro-Oncology Advances
IF4.1
2026-09-010
OAAI
Anna Cho, MD, PhD; Thore Jankowski, MD; Yiru Chen, MD; Lukas Kohlmaier, MD; Brigitte Gatterbauer, MD; Philip Lederer, MD; Lukas Haider, MD, PhD; D I Sonja Tögl, Bsc; Karl Rössler, MD; Christian Dorfer, MD, MBA; Philippe Dodier, MD, PhD; Christoph Höller, MD; Rupert Bartsch, MD; Maximilian J Hochmair, MD; Josa M Frischer, MD, PhD
Adjuvant alectinib versus chemotherapy in resected ALK- positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial

辅助阿来替尼与化疗在切除后的ALK阳性非小细胞肺癌（ALINA）：一项随机、开放标签、III期试验的健康相关生活质量与安全性结果

Lancet Oncology
IF35.9
2026-08-010
OAAI
Dziadziuszko, Rafal; Ahn, Jin Seok; Barlesi, Fabrice; Solomon, Benjamin J.; Wu, Yi-Long; Bondarenko, Igor; Hochmair, Maximilian; Horinouchi, Hidehito; Lee, Dae Ho; Lee, Jong-Seok; Planchard, David; Rittmeyer, Achim; Zhong, Wenzhao; Adler, Leah; Archer, Venice; Cardona, Andres; Petric, Patricia; Scalori, Astrid; Ding, Beiying; Mamolo, Carla; Smoljanovic, Vlatka; Nishio, Makoto
Structured Expert Elicitation of Long-Term Survival in Non-small Cell Lung Cancer: A Case Study Applying Guidance from NICE Technical Support Document 26

非小细胞肺癌长期生存的结构化专家评估：一项应用NICE技术支持文件26指导的案例研究

Applied Health Economics and Health Policy
IF3.3
2026-05-110
OAAI
Jessica E. Forsyth; Monika Achra; Javier Baena Espinar; Maximilian Hochmair; Astra M. Liepa; Alan Lenox-Smith; Tarun Puri; Rahul Rajesh; Michael D. Sonksen; Yvonne Summers; Anthonie J. van der Wekken; Min-Hua Jen; Shijie Ren
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC

SUNRAY-01试验方案：一项关于olomorasib和pembrolizumab联合或不联合化疗治疗KRAS G12C NSCLC的创新性研究设计

Future Oncology
IF2.6
2026-04-060
PRE
Solange Peters; Maximilian Hochmair; Kathryn C. Arbour; Luis Paz-Ares Rodriguez; Martin Reck; Ticiana Leal; Colin R. Lindsay; Lu Shun; William Nassib William; Alexander I. Spira; Joshua K. Sabari; Bjørn Henning Grønberg; Makoto Nishio; Timothy F. Burns; Nicolas Girard; Frederico Capuzzo; Alyson Merced; Nicolas Fasnacht; Carla Visseren-Grul; Marcelo V. Negrao
Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

ALK阳性早期非小细胞肺癌切除患者的疾病特征和治疗结局：来自随机ALINA试验

Lung Cancer
IF4.4
2026-04-010
PRE
Barlesi, Fabrice; Ahn, Jin Seok; Solomon, Benjamin J.; Nishio, Makoto; Dziadziuszko, Rafal; Lee, Dae Ho; Lee, Jong-Seok; Zhong, Wenzhao; Horinouchi, Hidehito; Mao, Weimin; Hochmair, Maximilian; de Marinis, Filippo; Migliorino, Maria Rita; Bondarenko, Igor; Xu, Tingting; Bara, Ilze; Ding, Beiying; Ngiam, Celina; Petric, Patricia; Wu, Yi-Long
EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study

EGFR突变状态、治疗模式及辅助EGFR-TKI批准前的可切除早期非小细胞肺癌的结局：一项国际真实世界研究

Lung Cancer
IF4.4
2026-02-280
PRE
Steven H. Lin; Doreen A Kahangire; Saurabh P Nagar; Myung-Ju Ahn; Raafet Affi; Jason Agulnik; Jin–Yuan Shih; Maximilian J Hochmair; Amanda Tufman; Didier Debieuvre; Jason Chow; Maria Jimenez; Keith L. Davis; Martin Sandelin; Rajwanth R. Veluswamy
Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with ALK-positive non-small cell lung cancer

ALINA研究结果的大众语言摘要：alectinib与化疗相比，在ALK阳性非小细胞肺癌患者术后的应用

Future Science OA
IF2.1
2025-12-310
PRE
Wu, Yi-Long; Dziadziuszko, Rafal; Ahn, Jin Seok; Barlesi, Fabrice; Nishio, Makoto; Lee, Dae Ho; Lee, Jong-Seok; Zhong, Wenzhao; Horinouchi, Hidehito; Mao, Weimin; Hochmair, Maximilian; De Marinis, Filippo; Migliorino, Maria Rita; Bondarenko, Igor; Lu, Shun; Wang, Qun; Lohmann, Tania Ochi; Xu, Tingting; Cardona, Andres; Hiles, Laura; Noe, Johannes; Solomon, Benjamin J.
Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial
FUTURE ONCOLOGY
IF2.6
2025-12-010
PRE
Ahn, Myung-Ju; Delmonte, Angelo; Ghosh, Sharmistha; Hochmair, Maximilian; Yang, Tsung-Ying; Yang, James Chih-Hsin; Han, Ji-Youn; Hansen, Karin Holmskov; Wu, Yanyu; Wan, Yin; Lin, Huamao Mark; Kretz, Julian; Hupf, Bradley; Kurec, Ahmet Melih; Churchill, Eric N.; Fram, Robert J.; Cabasag, Citadel Jungco; Goriya, Vishal; Zhao, Yuzhe; Campelo, Maria Rosario Garcia
Durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer: outcomes in age, sex, and platinum subgroups from the phase 3 CASPIAN study

度伐利尤单抗联合铂类-依托泊苷治疗广泛期小细胞肺癌：CASPIAN III期研究中不同年龄、性别和铂类亚组的结果

Clinical Lung Cancer
IF3.3
2025-08-050
OAAI
Niels Reinmuth; Jonathan W. Goldman; Yuanbin Chen; Katsuyuki Hotta; Dmytro Trukhin; Galina Statsenko; Maximilian Hochmair; Mustafa Özgüroğlu; Jun Ho Ji; Marina Chiara Garassino; Artem Poltoratskiy; Francesco Verderame; Libor Havel; Igor Bondarenko; György Losonczy; Nikolay Conev; Shannon Kummer; Helen Mann; Priti Chugh; Tapashi Dalvi; Luis Paz-Ares
Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy

Pembrolizumab联合或不维持Olaparib用于转移性鳞状NSCLC，对一线Pembrolizumab加化疗有反应

JOURNAL OF THORACIC ONCOLOGY
IF20.8
2025-02-011
OAAI
Hochmair, Maximilian; Schenker, Michael; Dols, Manuel Cobo; Kim, Tae Min; Ozyilkan, Ozgur; Smagina, Maria; Leonova, Viktoriya; Kato, Terufumi; Fedenko, Alexander; De Angelis, Flavia; Rittmeyer, Achim; Gray, Jhanelle E.; Greystoke, Alastair; Aggarwal, Himani; Huang, Qinlei; Zhao, Bin; Lara-Guerra, Humberto; Nadal, Ernest
Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer

合并安全性分析及sotorasib相关不良事件的的管理在KRAS G12C突变型晚期非小细胞肺癌中的应用

ONCOLOGIST
IF4.2
2025-01-230
OA
Skoulidis, Ferdinandos; Li, Bob T.; Hochmair, Maximilian; Govindan, Ramaswamy; Vincent, Mark; van der Wekken, Anthonie J.; Reguart Aransay, Noemi; O'Byrne, Kenneth J.; Griesinger, Frank; Nishio, Makoto; Lindsay, Colin; Reinmuth, Niels; Paulus, Astrid; Papakotoulas, Pavlos; Kim, Sang-We; Ferreira, Carlos Gil; Pasello, Giulia; Duruisseaux, Michael; Gennatas, Spyridon; Dimou, Anastasios; Mehta, Bhakti; Kormany, William; Nduka, Chidozie; Sylvester, Brooke E.; Ardito-Abraham, Christine; Wang, Yang; de Langen, Adrianus Johannes
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy

EGFR突变的非小细胞肺癌的小细胞转化: DLL3的表达和免疫检查点抑制剂或酪氨酸激酶抑制剂联合化疗的疗效

EUROPEAN JOURNAL OF CANCER
IF7.1
2024-12-010
OAAI
Saalfeld, Felix Carl; Moeller, Johanna; Christopoulos, Petros; Wenzel, Carina; Rasokatf, Anna; Wangg, Xuejun Alice; Vathiotish, Ioannis; Koenigi, David; Illinij, Oliver; Grohe, Christian; Wiesweg, Marcel; Wesseler, Claas; Schubart, Christoph; Pelusi, Natalie; Rohde, Gernot; Overbeck, Tobias R.; Kirfel, Jutta; Alt, Juergen; Kauffmann-Guerrero, Diego; Griesingerv, Frank; Kulhavyw, Jonas; Allgaeuer, Michael; Klimovay, Anna; Schuetz, Maret; Aust, Daniela E.; Hochmairj, Maximilian J.; Rothschild, Sacha I.; Syrigos, Konstantinos N.; Veluswamy, Rajwanth; Michels, Sebastian; Stenzinger, Albrecht; Joehrens, Korinna; Wermke, Martin
Whole exome sequencing (WES) analyses from IMpower133 and 6-year (y) overall survival (OS) from IMbrella A in patients (pts) with extensive-stage small cell lung cancer (ESSCLC) treated with atezolizumab (atezo)

全外显子组测序(WES)分析来自IMpower133和IMbrella A研究6年(y)总生存期(OS)的数据，来自接受阿替利珠单抗(atezo)治疗的广泛期小细胞肺癌(ESSCLC)患者(pts)。

ANNALS OF ONCOLOGY
IF65.4
2024-12-011
PRE
Kao, S. C-H.; Reck, M.; Liu, S. V.; Dziadziuszko, R.; Hochmair, M. J.; Huemer, F.; Gilberto de Castro, J.; Bernabe Caro, R.; Kim, S. H.; Kowalski, D. M.; Andric, Z. G.; Oancea, M.; Kaul, M.; Li, H.; Danner, B.; Lee, M. C.; Nabet, B. Y.; Sugawara, S.

研究方向

暂未获取到该数据
C
Christoph Weinlinger
H 指数:8论文数:50被引数:253
O
Oliver Illini
H 指数:9论文数:37被引数:245
H
Hannah Fabikan
H 指数:10论文数:52被引数:325
E
Enriqueta Felip
H 指数:129论文数:1,499被引数:11.1万
S
Sanjay Popat
H 指数:65论文数:804被引数:3.0万
I
Igor Bondarenko
H 指数:85论文数:667被引数:5.7万
A
Arschang Valipour
H 指数:39论文数:260被引数:5,685
J
James Chih‐Hsin Yang
H 指数:141论文数:1,223被引数:10.9万
N
Nir Peled
H 指数:75论文数:561被引数:4.2万
M
Martin Reck
H 指数:79论文数:639被引数:5.8万